Expression of CD44 variants in osteosarcoma |
| |
Authors: | M Kuryu T Ozaki K Nishida M Shibahara A Kawai H Inoue |
| |
Institution: | (1) Department of Orthopaedic Surgery, Faculty of Medicine, Okayama University Medical School, Okayama 700-8558, Japan Tel.: +81-86-235-7273 Fax: +81-86-223-9727 E-mail: tozaki@med.okayama-u.ac.jp, JP |
| |
Abstract: | The standard form of CD44 (CD44H) is a transmembranous glycoprotein, widely distributed on a variety of human lymphoid cells,
epithelial cells and tumours. CD44 has many variant forms, which are generated by alternative splicing. In recent years, CD44
has been reported to be related to the degree of tumour differentiation, tumour cell invasion, and metastasis. We investigated
44 tumour specimens in 39 patients with osteosarcoma immunochemically to analyse the expression of CD44 standard (CD44H) and
variant exon-encoded gene products (CD44v3, v4, v5, v6, v7, v9, and v10). Furthermore, the relationship between CD44 expression
and the clinical outcome of patients with osteosarcoma was analysed. Membrane accentuation and exclusive cytoplasmic reactivity
were analysed as separate staining patterns. Tumour cells and some multinucleated giant cells were markedly stained. CD44H,
v3, v4, v5, v6, v7, v9, and v10 were expressed in 85%, 49%, 54%, 59%, 46%, 5%, 28%, and 10% of the specimens respectively.
The cumulative 5-year metastasis-free survival was 58% in CD44v6-negative cases and 24% in CD44v6-positive cases (P=0.046). However, the cumulative 5-year metastasis-free survival was not significantly different between cases positive and
negative for other variants of CD44. Multivariate analysis (Cox proportional-hazard model) with CD44v6 expression (positive
or negative), chemotherapy (intensive or non-intensive), tumour site (proximal or distal), and age (at least 30 years or less
than 30 years) showed that expression of CD44v6 and chemotherapy were important prognostic factors in patients with osteosarcoma.
Overexpression of CD44 isoforms containing variant v6 is correlated with poor prognosis in patients with osteosarcoma.
Received: 4 March 1999 / Accepted: 7 June 1999 |
| |
Keywords: | Osteosarcoma CD44 Immunohisto-chemistry Prognosis |
本文献已被 SpringerLink 等数据库收录! |
|